Cutler Group’s Amphastar Pharmaceuticals AMPH Stock Holding History

Cutler Group’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-900	Closed	-$1K	–	4364
2017 Q4	$1K	Buy	+900	New	+$16.8K	﹤0.01%	4345

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cutler Group's AMPH Position: Q4 2017 in Review

Cutler Group sold out of Amphastar Pharmaceuticals (AMPH) in Q4 2017, closing a stake of 100 shares — an estimated $1.87K sold.

Cutler Group first reported a position in AMPH in Q3 2016 and held it in 5 quarters. The position peaked at $47K in Q3 2016. 109 funds tracked by Wall St. Rank hold AMPH as of Q4 2017.

Cutler Group reported no remaining Amphastar Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Cutler Group sold 100 Amphastar Pharmaceuticals shares in Q4 2017, an estimated $1.87K.
Cutler Group first reported a position in Amphastar Pharmaceuticals in Q3 2016 and held it in 5 quarters.
Cutler Group's Amphastar Pharmaceuticals position peaked at $47K in Q3 2016.
109 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q4 2017.

Based on Cutler Group's 13F filing for Q4 2017, filed 17 Jan 2018.